Free Trial
NASDAQ:TRVI

Trevi Therapeutics (TRVI) Stock Price, News & Analysis

Trevi Therapeutics logo
$6.49 +0.02 (+0.31%)
As of 11:18 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Trevi Therapeutics Stock (NASDAQ:TRVI)

Key Stats

Today's Range
$6.50
$6.68
50-Day Range
$4.26
$6.81
52-Week Range
$2.30
$7.39
Volume
348,713 shs
Average Volume
1.11 million shs
Market Capitalization
$627.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.56
Consensus Rating
Buy

Company Overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
72nd Percentile Overall Score

TRVI MarketRank™: 

Trevi Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 272nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Trevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.30, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Trevi Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Trevi Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Trevi Therapeutics are expected to decrease in the coming year, from ($0.49) to ($0.51) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Trevi Therapeutics is -14.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Trevi Therapeutics is -14.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Trevi Therapeutics has a P/B Ratio of 5.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Trevi Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.17% of the float of Trevi Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently increased by 7.45%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Trevi Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Trevi Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.17% of the float of Trevi Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Trevi Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Trevi Therapeutics has recently increased by 7.45%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Trevi Therapeutics has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Trevi Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for TRVI on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Trevi Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -55% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $583,493.00 in company stock.

  • Percentage Held by Insiders

    24.37% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.76% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Trevi Therapeutics' insider trading history.
Receive TRVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trevi Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRVI Stock News Headlines

Trevi Therapeutics management to meet virtually with B. Riley
Trevi Therapeutics management to meet with Cantor Fitzgerald
This isn’t a trade war. It’s worse…
Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin investing? The rise in sports betting? A loneliness and opioid epidemic? This is America in 2025. But these aren't societal problems... they're economic ones. And they're NOT your fault. One investigative journalist is breaking what he calls "the most important money story of our lifetimes"; on this page here. It's the REAL story about Trump's economic agenda.
Trevi Therapeutics price target raised to $20 from $11 at B. Riley
See More Headlines

TRVI Stock Analysis - Frequently Asked Questions

Trevi Therapeutics' stock was trading at $4.12 at the start of the year. Since then, TRVI stock has increased by 57.9% and is now trading at $6.5050.
View the best growth stocks for 2025 here
.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) posted its quarterly earnings data on Tuesday, March, 18th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01.
Read the conference call transcript
.

Trevi Therapeutics (TRVI) raised $70 million in an initial public offering (IPO) on Tuesday, May 7th 2019. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets acted as the underwriters for the IPO and Needham & Company was co-manager.

Top institutional shareholders of Trevi Therapeutics include Oppenheimer & Co. Inc. (0.10%), Rhumbline Advisers (0.09%), Vontobel Holding Ltd. (0.03%) and Diversified Trust Co (0.02%). Insiders that own company stock include Tpg Gp A, Llc, Thomas Sciascia, Farrell Simon and Lisa Delfini.
View institutional ownership trends
.

Shares of TRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trevi Therapeutics investors own include JPMorgan Chase & Co. (JPM), Predictive Oncology (POAI), Ford Motor (F), Tesla (TSLA), Meta Platforms (META), Abbott Laboratories (ABT) and Bank of America (BAC).

Company Calendar

Last Earnings
3/18/2025
Today
4/27/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TRVI
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.56
High Stock Price Target
$29.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+171.4%
Consensus Rating
Buy
Rating Score (0-4)
3.30
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-29,070,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$1.29 per share
Price / Book
5.02

Miscellaneous

Free Float
58,134,000
Market Cap
$625.53 million
Optionable
Optionable
Beta
0.41
10 Stocks Set to Soar in Spring 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:TRVI) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners